Compare HBIO & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | BCTX |
|---|---|---|
| Founded | 1901 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 28.8M |
| IPO Year | 2000 | 2025 |
| Metric | HBIO | BCTX |
|---|---|---|
| Price | $0.49 | $3.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.50 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 377.0K | 180.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,176,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.80 | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $0.61 |
| 52 Week High | $0.95 | $14.68 |
| Indicator | HBIO | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 38.63 |
| Support Level | $0.47 | $3.60 |
| Resistance Level | $0.55 | $4.42 |
| Average True Range (ATR) | 0.04 | 0.27 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 6.33 | 26.15 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.